Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non–Small Cell Lung Cancer

This study assessed the effects of tislelizumab, a programmed cell death protein 1 inhibitor, in combination with chemotherapy versus chemotherapy alone as first-line treatment on health-related quality of life (HRQoL) in patients with advanced nonsquamous non–small cell lung cancer (nSQ-NSCLC). MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Shun, Yu, Yan, Barnes, Gisoo, Qiu, Xiusong, Bao, Yuanyuan, Tang, Boxiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974185/
https://www.ncbi.nlm.nih.gov/pubmed/35333492
http://dx.doi.org/10.1097/PPO.0000000000000583

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974185/
https://www.ncbi.nlm.nih.gov/pubmed/35333492
http://dx.doi.org/10.1097/PPO.0000000000000583

Ejemplares similares